The NICE Implementation Collaborative (NIC) NIC harnesses the skills, experience and dedication of organisations and individuals from across the healthcare system to improve patient outcomes for all. The NIC is a unique partnership whose members are committed to working together to support a system where patients have faster and more consistent access to NICE-recommended medicines, treatments and technologies.
This independent partnership between the NHS, the life sciences industry, healthcare professional bodies, key health organisations and the public is transformational and heralds a collaborative approach that will be critical in achieving improved outcomes for the whole population. The signing of the NIC concordat by all its partners is the very first time that the NHS and it's stakeholders have come together to work in this way and completely re-draws the landscape.
The Academy has signed up to the NIC Concordat which can be read here.
The NIC brings together all the key players in one place to find out what's stopping NICE treatments being used and then aims to find ways to overcome these barriers, in the new environment of CCGs locally determining appropriate and affordable prioritisation.
- Denosumab for post-menopausal women with osteoporosis (NICE TA204)
- Novel Oral Anti-coagulants for prevention of stroke in patients with a trial fibrillation (NICE TA 249 & 256)
- Insulin pumps in type I diabetes mellitus (TA151)
- Natriuretic peptide testing in heart failure (CG108)
Members of the NIC: